FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2028163816> ?p ?o ?g. }

• W2028163816 endingPage "1374" @default.
• W2028163816 startingPage "1365" @default.
• W2028163816 abstract "Poly(ADP-ribose) is synthesized from nicotinamide adenine dinucleotide by poly(ADP-ribose) polymerase (PARP) and degraded by poly(ADP-ribose) glycohydrolase (PARG). The activation of the PARP/PARG pathway has been found in a variety of animal models of diseases, including septic shock-like syndrome. We have previously demonstrated that PARP inhibition by 3-ami-nobenzamide or GPI 6150 ameliorates multiple organ dysfunctions induced by zymosan. In the present study, we investigated whether similar effect could be achieved through PARG inhibition to break the cycle of poly(ADP-ribose) turnaround.Experimental study.University laboratory.Male CD mice (20-22 g).We tested the effects of GPI 18214 (40 mg/kg intraperitoneally bolus), a novel and potent PARG inhibitor, at 1 and 6 hr after zymosan (500 mg/kg, administered intraperitoneally as a suspension in saline) on the development of septic shock-like syndrome in mice. Organ failure and systemic inflammation in mice were assessed 18 hrs after administration of zymosan and/or GPI 18214 and monitored for 12 days (for loss of body weight and mortality).At 18 hrs after zymosan administration, we found a significant increase of peritoneal exudates, leukocyte infiltration in peritoneal cavity as well as an infiltration of neutrophils in lung and ileum tissues and subsequent lipid peroxidation, and increased production of plasma tumor necrosis factor-alpha and interleukin-1 beta. Furthermore, zymosan administration induced significant liver, lung, pancreas, intestine, and kidney dysfunction as well as a systemic toxicity and significant loss of body weight. At the end of observation period (12 days), 90% of zymosan-treated mice were dead. GPI 18214 (40 mg/kg intraperitoneally, 1 and 6 hrs after zymosan) treatment significantly reduced peritoneal exudates, inflammatory cell infiltration, and organ injury and mortality rate in zymosan-treated mice.This study supports early studies that show efficacy from blocking the poly(ADP-ribose) pathway in septic shock-like syndrome model. It provides evidence that GPI 18214, a PARG inhibitor, attenuates the degree of zymosan-induced nonseptic shock in mice, suggesting that PARG may be an alternative therapeutic target for shock treatment." @default.
• W2028163816 created "2016-06-24" @default.
• W2028163816 creator A5010437948 @default.
• W2028163816 creator A5011577581 @default.
• W2028163816 creator A5014158637 @default.
• W2028163816 creator A5034283699 @default.
• W2028163816 creator A5053839749 @default.
• W2028163816 creator A5068588397 @default.
• W2028163816 creator A5073501391 @default.
• W2028163816 creator A5074289588 @default.
• W2028163816 creator A5084349553 @default.
• W2028163816 date "2004-06-01" @default.
• W2028163816 modified "2023-10-13" @default.
• W2028163816 title "Treatment with a novel poly(ADP-ribose) glycohydrolase inhibitor reduces development of septic shock-like syndrome induced by zymosan in mice" @default.
• W2028163816 cites W1964531991 @default.
• W2028163816 cites W1967727360 @default.
• W2028163816 cites W1983310681 @default.
• W2028163816 cites W1994011134 @default.
• W2028163816 cites W1994906169 @default.
• W2028163816 cites W1997253947 @default.
• W2028163816 cites W1997875323 @default.
• W2028163816 cites W2011151958 @default.
• W2028163816 cites W2016232887 @default.
• W2028163816 cites W2017698823 @default.
• W2028163816 cites W2036682827 @default.
• W2028163816 cites W2047751863 @default.
• W2028163816 cites W2048190045 @default.
• W2028163816 cites W2052421682 @default.
• W2028163816 cites W2059933894 @default.
• W2028163816 cites W2065857711 @default.
• W2028163816 cites W2067668320 @default.
• W2028163816 cites W2068315715 @default.
• W2028163816 cites W2079561932 @default.
• W2028163816 cites W2081237387 @default.
• W2028163816 cites W2086584071 @default.
• W2028163816 cites W2090110157 @default.
• W2028163816 cites W2111015429 @default.
• W2028163816 cites W2116118256 @default.
• W2028163816 cites W2116638383 @default.
• W2028163816 cites W2153053799 @default.
• W2028163816 doi "https://doi.org/10.1097/01.ccm.0000127775.70867.0c" @default.
• W2028163816 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15187521" @default.
• W2028163816 hasPublicationYear "2004" @default.
• W2028163816 type Work @default.
• W2028163816 sameAs 2028163816 @default.
• W2028163816 citedByCount "50" @default.
• W2028163816 countsByYear W20281638162012 @default.
• W2028163816 countsByYear W20281638162013 @default.
• W2028163816 countsByYear W20281638162014 @default.
• W2028163816 countsByYear W20281638162016 @default.
• W2028163816 countsByYear W20281638162017 @default.
• W2028163816 countsByYear W20281638162019 @default.
• W2028163816 countsByYear W20281638162021 @default.
• W2028163816 countsByYear W20281638162022 @default.
• W2028163816 countsByYear W20281638162023 @default.
• W2028163816 crossrefType "journal-article" @default.
• W2028163816 hasAuthorship W2028163816A5010437948 @default.
• W2028163816 hasAuthorship W2028163816A5011577581 @default.
• W2028163816 hasAuthorship W2028163816A5014158637 @default.
• W2028163816 hasAuthorship W2028163816A5034283699 @default.
• W2028163816 hasAuthorship W2028163816A5053839749 @default.
• W2028163816 hasAuthorship W2028163816A5068588397 @default.
• W2028163816 hasAuthorship W2028163816A5073501391 @default.
• W2028163816 hasAuthorship W2028163816A5074289588 @default.
• W2028163816 hasAuthorship W2028163816A5084349553 @default.
• W2028163816 hasConcept C104317684 @default.
• W2028163816 hasConcept C126322002 @default.
• W2028163816 hasConcept C134018914 @default.
• W2028163816 hasConcept C182979987 @default.
• W2028163816 hasConcept C202751555 @default.
• W2028163816 hasConcept C203014093 @default.
• W2028163816 hasConcept C2777628635 @default.
• W2028163816 hasConcept C2778384902 @default.
• W2028163816 hasConcept C2778754761 @default.
• W2028163816 hasConcept C2778870864 @default.
• W2028163816 hasConcept C2779138821 @default.
• W2028163816 hasConcept C55493867 @default.
• W2028163816 hasConcept C71924100 @default.
• W2028163816 hasConcept C82381507 @default.
• W2028163816 hasConcept C86803240 @default.
• W2028163816 hasConcept C98274493 @default.
• W2028163816 hasConceptScore W2028163816C104317684 @default.
• W2028163816 hasConceptScore W2028163816C126322002 @default.
• W2028163816 hasConceptScore W2028163816C134018914 @default.
• W2028163816 hasConceptScore W2028163816C182979987 @default.
• W2028163816 hasConceptScore W2028163816C202751555 @default.
• W2028163816 hasConceptScore W2028163816C203014093 @default.
• W2028163816 hasConceptScore W2028163816C2777628635 @default.
• W2028163816 hasConceptScore W2028163816C2778384902 @default.
• W2028163816 hasConceptScore W2028163816C2778754761 @default.
• W2028163816 hasConceptScore W2028163816C2778870864 @default.
• W2028163816 hasConceptScore W2028163816C2779138821 @default.
• W2028163816 hasConceptScore W2028163816C55493867 @default.
• W2028163816 hasConceptScore W2028163816C71924100 @default.
• W2028163816 hasConceptScore W2028163816C82381507 @default.
• W2028163816 hasConceptScore W2028163816C86803240 @default.
• W2028163816 hasConceptScore W2028163816C98274493 @default.
• W2028163816 hasIssue "6" @default.

• next